World of DTC Marketing
AUGUST 12, 2022
Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. The most telling data on a disconnect between drug prices and research costs has received almost no public attention.
Pharmaceutical Technology
JANUARY 12, 2023
The drug is being developed by AstraZeneca and Avillion under a co-development agreement signed in March 2018. Physicians will be able to offer their patients Airsupra, an important new rescue treatment that reduces the risk of asthma exacerbations.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 24, 2023
For example, the cost of Humira biosimilars in Denmark decreased by 82% from September 2018 to December 2018. Further, there remains scepticism on the efficacy and safety of biosimilars. Since Humira biosimilars entered Europe, they have been noted to cause steep discounts in price, higher uptake, and big cost savings.
PM360
SEPTEMBER 15, 2022
based physicians reveals that a majority are concerned and confused about what constitutes a life-threatening emergency that would make an abortion procedure legal in those 11 states where it has been banned. BrainsWay’s coils are housed in a cushioned helmet and have been used to stimulate one portion of the brain to treat OCD since 2018.
European Pharmaceutical Review
MARCH 4, 2024
Therefore, biologics identification and characterisation poses unparalleled challenges, as does their manufacturing processes and routes of administration while maintaining patient safety and clinical efficacy. Dave Li, PhD Dave Li is a principal consultant and Clinical Research Physician with KCR. References 1. cited 2024Jan].
pharmaphorum
SEPTEMBER 16, 2022
The week 16 data of lebrikizumab […] points towards a drug with robust efficacy with hardly any safety trade-offs. Despite this, there are still remaining unmet needs in moderate to severe AD, mainly around getting robust efficacy over time without safety tradeoffs and better convenience regimens.”. About the interviewee.
Clarivate
MAY 24, 2022
6] [7] However, in May 2018, the National Health Commission of China (NHC), together with four other national agencies, formulated China’s First List of Rare Diseases (CRDL) to provide a foundation for policymaking around rare disease treatments. 2018; 40:432-434. (in Source: Clarivate analysis. 10] [11] [12]. 10] [11] [12].
Expert insights. Personalized for you.
255 
Let's personalize your content